South Dakota Investment Council Purchases 300 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

South Dakota Investment Council grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,084 shares of the medical research company’s stock after purchasing an additional 300 shares during the quarter. South Dakota Investment Council’s holdings in Thermo Fisher Scientific were worth $1,106,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in TMO. GAMMA Investing LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $1,288,000. Harbor Advisors LLC grew its position in Thermo Fisher Scientific by 50.0% in the 4th quarter. Harbor Advisors LLC now owns 3,000 shares of the medical research company’s stock valued at $1,592,000 after purchasing an additional 1,000 shares during the period. Linden Thomas Advisory Services LLC grew its position in Thermo Fisher Scientific by 15.4% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 1,784 shares of the medical research company’s stock valued at $947,000 after purchasing an additional 238 shares during the period. Monument Group Wealth Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $425,000. Finally, Marks Group Wealth Management Inc grew its position in Thermo Fisher Scientific by 6.0% in the 4th quarter. Marks Group Wealth Management Inc now owns 8,857 shares of the medical research company’s stock valued at $4,701,000 after purchasing an additional 504 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock valued at $28,513,384 over the last quarter. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Royal Bank of Canada lifted their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Raymond James lifted their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. HSBC lifted their target price on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Finally, The Goldman Sachs Group boosted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $602.81.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $577.62 on Thursday. The firm has a market cap of $220.48 billion, a PE ratio of 37.39, a price-to-earnings-growth ratio of 2.42 and a beta of 0.80. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. The business has a 50 day moving average price of $572.61 and a 200-day moving average price of $529.06.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.